Tumor marker studies in patients with ovarian cancer showed a trend of decreasing tumor growth, accompanied by decreasing cancer antigen 72-4, aka tumor-associated glycoprotein 72, with increasing administered radioactivity.
← all excerpts
Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation.
1
—
—